Drug intelligence / Profile preview

PepGNP-COVID19

Development stage: Phase 2
Lead developer: Gylden Pharma
Modality: Nanoparticles → Drug Delivery Systems, Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular (inferred, Typical For Vaccines)

Overview

PepGNP-COVID19 is a nanoparticle-based peptide vaccine candidate developed for the prevention of COVID-19. The formulation likely involves gold nanoparticles (GNP) conjugated with synthetic peptides derived from SARS-CoV-2 antigens, designed to elicit an immune response against the virus. This approach leverages the immunogenic properties of peptide epitopes and the adjuvant effect of gold nanoparticles to enhance vaccine efficacy. The primary indication is prophylaxis against COVID-19 infection.

Brand names: PepGNP-COVID19PepGNP-COVID-19PepGNP-COVID 19
Other names: PepGNP-COVID19PepGNP-COVID-19PepGNP-COVID 19

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on PepGNP-COVID19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PepGNP-COVID19.

Explore the full profile